Petros Pharmaceuticals (PTPI)
(Delayed Data from NSDQ)
$0.61 USD
+0.03 (4.92%)
Updated May 31, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PTPI 0.61 +0.03(4.92%)
Will PTPI be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PTPI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for PTPI
Buy Rating Justified for Petros Pharmaceuticals Amid AI Integration and Strategic OTC Expansion
Petros Pharmaceuticals completes human factors study of AI-integrated web app
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch
12 Health Care Stocks Moving In Wednesday's After-Market Session
Buy Rating Affirmed for Petros Pharmaceuticals Amidst Strategic Shift to OTC Market and Positive Regulatory Prospects